全外显子测序在糖尿病肾病中的应用

doi:10.20047/j.issn1673-7210.2023.13.08

Abstract
Figure/Table
References (35)
Related Citation (15)

Download: PDF (474 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Diabetic kidney disease (DKD), as one of the most common complications of diabetes mellitus, which is characterized by microvascular damage of renal dysfunction. DKD is the first cause of end stage renal failure, but its specific occurrence and development mechanism is complex. Clinical and epidemiological evidence shows that DKD has familial aggregation in different ethnic groups, suggesting that genetic factors are involved in the progression of the disease. Whole exon sequencing (WES) includes the capture, sequencing, and analysis of all exons in the human genome. This paper aims to summarize the latest progress of WES in DKD, hoping to develop new targets for future clinical diagnosis and treatment.

Key words： Diabetic kidney disease Whole exon sequencing Target therapy Precision medicine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Zehui　YANG Mengru　MA Sha　MA Qiang　HAN Rui

Cite this article:

LIU Zehui　YANG Mengru　MA Sha　MA Qiang　HAN Rui. Application of whole exon sequencing in diabetic kidney disease[J]. 中国医药导报, 2023, 20(13): 37-40.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.13.08 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I13/37

[1] 李法君.外显子组测序技术的原理及应用概述[J].生物学教学，2018，43（2）：77-79.
[2] Petersen BS，Fredrich B，Hoeppner MP，et al. Opportunities and challenges of whole-genome and -exome sequencing [J]. BMC Genet，2017，18（1）：14.
[3] Zhang D，Dai L，Zhou Z，et al. Homozygosity mapping and whole exome sequencing reveal a novel ERCC8 mutation in a Chinese consanguineous family with unique cerebellar ataxia [J]. Clin Chim Acta，2019，494：64-70.
[4] Aggarwal S. Role of whole exome sequencing for unidentified genetic syndromes [J]. Curr Opin Obstet Gynecol，2021，33（2）：112-122.
[5] van Dijk EL，Jaszczyszyn Y，Naquin D，et al. The Third Revolution in Sequencing Technology [J]. Trends Genet，2018， 34（9）：666-681.
[6] Stessman HA，Bernier R，Eichler EE. A genotype-first approach to defining the subtypes of a complex disease [J]. Cell，2014，156（5）：872-877.
[7] Daios S，Kaiafa G，Pilalas D，et al. Endothelial Dysfunction and Platelet Hyperaggregation in Type 2 Diabetes Mellitus：The Era of Novel Anti-diabetic Agents [J]. Curr Med Chem，2021，28（20）：3935-3963.
[8] Roy A，Maiti A，Sinha A，et al. Kidney Disease in Type 2 diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors：A Consensus Statement [J]. Diabetes Ther，2020， 11（12）：2791-2827.
[9] Fu H，Liu S，Bastacky SI，et al. Diabetic kidney diseases revisited：A new perspective for a new era [J]. Mol Metab，2019，30：250-263.
[10] Murphy D，McCulloch CE，Lin F，et al. Trends in Prevalence of Chronic Kidney Disease in the United States [J]. Ann Intern Med，2016，165（7）：473-481.
[11] American Diabetes Association. 11. Microvascularcomplications and foot care：standards of medical care in diabetes-2020 [J]. Diabetes Care，2020，43（Suppl 1）：S135- S151.
[12] Zhang L，Long J，Jiang W，et al. Trends in chronic kidney disease in China [J]. N Engl J Med，2016，375（9）：905- 906.
[13] Singh S，Sonkar SK，Sonkar GK，et al. Diabetic kidney disease：A systematic review on the role of epigenetics as diagnostic and prognostic marker [J]. Diabetes Metab Res Rev， 2019，35（5）：e3155.
[14] Gheith O，Farouk N，Nampoory N，et al. Diabetic kidney disease：worldwide difference of prevalence and risk factors [J]. J Nephropharmacol，2016，5（1）：49-56.
[15] Ahlqvist E，van Zuydam NR，Groop LC，et al. The genetics of diabetic complications [J]. Nat Rev Nephrol，2015，11（5）：277-287.
[16] Ruospo M，Saglimbene VM，Palmer SC，et al. Glucose targets for preventing diabetic kidney disease and its progression [J]. Cochrane Database Syst Rev，2017，6（6）：CD01 0137.
[17] Kato M，Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory [J]. Nat Rev Nephrol，2019，15（6）：327-345.
[18] Cole JB，Florez JC. Genetics of diabetes mellitus and diabetes complications [J]. Nat Rev Nephrol，2020，16（7）：377-390.
[19] Keating ST，van Diepen JA，Riksen NP，et al. Epigenetics in diabetic nephropathy，immunity，and metabolism [J]. Diabetologia，2018，61（1）：6-20.
[20] Thomas MC. Epigenetic Mechanisms in Diabetic Kidney Disease [J]. Curr Diab Rep，2016，16（3）：31.
[21] Hung PH，Hsu YC，Chen TH，et al. Recent Advances in Diabetic Kidney Diseases：From Kidney Injury to Kidney Fibrosis [J]. Int J Mol Sci，2021，22（21）：11857.
[22] Wang Y，Zhao Y，Zhang J，et al. A case of a novel mutation in HNF1β-related maturity-onset diabetes of the young type 5 with diabetic kidney disease complication in a Chinese family [J]. J Diabetes Complications，2017，31（7）：1243-1246.
[23] Wang Y，Zhang J，Zhao Y，et al. COL4A3 Gene Variants and Diabetic Kidney Disease in MODY [J]. Clin J Am Soc Nephrol，2018，13（8）：1162-1171.
[24] Kataoka-Yahiro MR，Davis J，Rhee CM，et al. Racial/Ethnic Differences in Early Detection and Screening for Chronic Kidney Disease Among Adults in Hawaii：A 10- Year Population Health Study [J]. Prev Chronic Dis，2020， 17：E84.
[25] Bhalla V，Zhao B，Azar KM，et al. Racial/ethnic differences in the prevalence of proteinuric and nonproteinuric diabetic kidney disease [J]. Diabetes Care，2013，36（5）：1215-1221.
[26] Hanson RL，Craig DW，Millis MP，et al. Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide ingle nucleotide polymorphism association study [J]. Diabetes，2007，56（4）：975-983.
[27] Akhtar M，Taha NM，Nauman A，et al. Diabetic Kidney Disease：Past and Present [J]. Adv Anat Pathol，2020，27（2）：87-97.
[28] Lin J，Cheng A，Cheng K，et al. New Insights into the Mechanisms of Pyroptosis and Implications for Diabetic Kidney Disease [J]. Int J Mol Sci，2020，21：7057.
[29] Fang M，Kang L，Wang X，et al. Inhibition of core fucosylation limits progression of diabetic kidney disease [J]. Biochem Biophys Res Commun，2019，520（3）：612-618.
[30] Oltean S，Qiu Y，Ferguson JK，et al. Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy [J]. J Am Soc Nep- hrol，2015，26（8）：1889-1904.
[31] Shaik F，Cuthbert GA，Homer-Vanniasinkam S，et al. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy [J]. Biomolecules，2020，10（12）：1673.
[32] Boudria A，Abou Faycal C，Jia T，et al. VEGF-A165b，a splice variant of VEGF-A，promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop [J]. Oncogene，2019，38（7）： 1050-1066.
[33] Kikuchi R，Stevens M，Harada K，et al. Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease [J]. Adv Clin Chem，2019，88：1-33.
[34] Stevens M，Neal CR，Salmon AHJ，et al. VEGF-A165b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney [J]. J Physiol，2017，595（19）：6281-6298.
[35] Miao C，Zhu X，Wei X，et al. Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases [J]. Ren Fail，2022，44（1）：881-892.